![\"Production](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2025\/12\/GettyImages-1369174756-scaled.jpg\")
<\/p>\n<\/p>\n
Vasomune Therapeutics has entered into an agreement with the pharmaceutical company AnGes to expand indications for the drug candidate they are developing to treat vascular damage. The partnership will bring $4 million in funding to the start-up to continue operations, expand indications and bring drug development back to Canada.<\/p>\n
\u201cWe\u2019re pleased to continue to advance this technology with a trusted partner who shares our vision,\u201d says Brian Jahns, President and CEO of Vasomune. \u201cThis expanded agreement brings us closer to mitigating pathological vascular damage in a range of conditions.\u201d<\/p>\n
Vasomune was created in 2014 based on research from the laboratory of the late Dr. Daniel J. Dumont at Sunnybrook Research Institute (SRI). Vasomune\u2019s novel lead therapeutic,\u00a0AV-001\u00a0targets vascular leakage which causes blood plasma to leak out of vessels into surrounding tissues, causing edema and low blood pressure. It is a central feature of acute respiratory distress syndrome (ARDS), when fluid builds up in the lungs restricting breathing and oxygen levels. Effective management is critical in severe respiratory illnesses, while antibiotics begin to take effect.<\/p>\n
Now, with the support from AnGes, Vasomune is looking to expand indications beyond ARDS, including for cerebral vascular damage in patients undergoing hemodialysis and for patients with thermal burns.<\/p>\n
With the new funding, Vasomune also intends to bring operations and manufacturing back to Canada to ensure supply chain stability.<\/p>\n
\u201cDuring COVID, we saw how global supply chains were interrupted,\u201d says Jahns. \u201cWe\u2019re focused on moving manufacturing onshore to ensure our drug is available to Canadians in the event of an emergency response and to give biotech and health care in Canada an opportunity to shine.\u201d<\/p>\n
Vasomune is currently in the midst of a phase II trial of AV-001 for ARDS, and is looking ahead to launching a new trial in patients with hemodialysis next year.<\/p>\n
\u201cThis is an amazing step for one of Canada\u2019s most promising sleeper companies,\u201d says Raphael Ronen, Director of Business Development at SRI. \u201cWe at Sunnybrook are very proud to see this technology and company continue to advance.\u201d\u00a0<\/p>\n